Pharmaceutical

Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis 

Arcutis Canada, has received Health Canada's approval for ZORYVE to treat seborrheic dermatitis in patients aged nine years and above.

Oct 22, 2024 - 04:00
Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis 
Arcutis Canada, has received Health Canada's approval for ZORYVE to treat seborrheic dermatitis in patients aged nine years and above.
Read the original article

Tags:

Previous Article

Sanofi’s $17bn sale of Opella to US investors advances following government deal

Next Article

Seaport raises $225m to advance portfolio of neuropsychiatric prodrugs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Microsoft and NVIDIA expand collaboration in healthcare innovation

Microsoft and NVIDIA expand collaboration in healthcare...

Mar 20, 2024

STAT+: In setback, Pfizer abandons one weight loss pill and bets on another

STAT+: In setback, Pfizer abandons one weight loss pill...

Jun 26, 2023

In pigs, researchers show ultrasound could be used for 3D printing inside the body

In pigs, researchers show ultrasound could be used for ...

Dec 7, 2023